Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simmitinib plus SG001 in Advanced Solid Tumors
NCT06132217Phase 2Not yet recruiting
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Cimetinib and PBI-1308 in solid tumor (6 cohorts), sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Primary endpoints: Dose Limited Toxicity, Maximum Tolerated Dose and 3 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
CimetinibPBI-1308
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06132217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132217.